texas oncology more breakthroughs. more victories

Minal Barve, M.D.

Minal Barve, M.D. Photo

Provider Type: Physician

Board Certifications:
  • Internal Medicine
  • Medical Oncology


General Summary

Dr. Barve is the Executive Medical Director and Chief Medical Officer for Mary Crowley Cancer Research in Dallas. Their focus is to develop novel treatments for cancer. She is also the Medical Director for GDAS (Greater Dallas Arya Samaj) Cancer Clinic, which provides care for indigent patients with curable cancers.


  • Fellowship in Medical Oncology (2001 – 2003)
    Baylor University Medical Center, Dallas, TX
  • Residency (1997 – 1999)
    Texas Health Presbyterian Hospital Dallas, Dallas, TX
  • Internship in Internal Medicine (1996 – 1997)
    Texas Health Presbyterian Hospital Dallas, Dallas, TX
  • Medical Doctorate (1987 – 1993)
    Dr. Panjabrao Deshmukh Memorial Medical College India

Accolades & Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • Indo-American Cancer Association
  • Tarrant County Medical Society
  • Texas Indo-American Physicians Society
  • Texas Medical Association

Dr. Barve was awarded second prize for Oral Abstract at Annual Associates meeting, Texas Chapter, American College of Physicians, Medical School Valedictorian, Graduating Class of 1993. Received Gold medals in: Obstetrics and Gynecology, Ophthalmology, Surgery and Anatomy, as well as Special awards in the fields of: ENT, Pediatrics, Preventive and Social Medicine, Medical Teacher’s Welfare Association and recognition in Indo-American Who’s Who & Reference Asia for outstanding academic achievement.


Show all Publications
  • Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients with Small-Cell Lung Cancer

    Clinical and Translational Science, 2020

  • LOXO-305 in Previously Treated Advanced B-Cell Malignancies

    Lancet Oncology, 2020

  • Phase 1 Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

    Molecular Cancer Therapeutics, 2020

  • First-in-Human Study of Mivebresib (ABBV- 075), an Oral Pan-Inhibitor of Bromodomain and Extra Tenninal Proteins, in Patients with Relapsed/Refractory Solid Tumors

    Clinical Cancer Research, 2019

  • Five-Year Results of a Phase II Trial of Preoperative 5-Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel With Capecitabine (wTX) (With Trastuzumab in HER2-Positive Patients) for Patients With Stage II or III Breast Cancer

    Cancer Medicine, 2018

  • Case Report: Immune Checkpoint Inhibitor Elicited Complete Response in a Heavily Pretreated Patient with Metastatic Endometrial Carcinoma with a High Tumor Mutation Burden (TMB)

    Molecular Medicine: Current Aspects, 2018

  • SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study

    Cancer Discovery, 2018

  • Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors

    Clinics in Oncology, 2017

  • Case Report: Immune Mediated Complete Response in a Patient with Recurrent Advanced Ewing's Sarcoma (EWS) Following Vigil® Immunotherapy

    Journal of Pediatric Hematology/Oncology, 2017

  • Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors

    Journal of Surgical Oncology and Clinical Research, 2017

  • Case Report: Immune-Mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

    J Pediatric Hematology/Oncology, 2017

  • Case Report: Immune-Mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

    J Pediatric Hematology/Oncology, 2017

  • Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma

    Molecular Therapy, 2016

  • Phase II Study of Vigil® DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer

    Gynecologic Oncology, 2016

  • Follow-up of bi-shRNAfurin /GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in Patients with Advanced Melanoma

    Biomedical Genetics and Genomics, 2016

  • Phase I Trial of bi-shRNA STMNl BIV in Refractory Cancer

    Molecular Therapy, 2015

  • Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

    Molecular Therapy, 2015

  • Summary of bi-shRNAfuri11/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

    Oncology, 2014

  • Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

    Molecular Therapy, 2013

  • Immune Response and Survival of Refractory Cancer Patients Who Received TGF-P2 Antisense/GM-CSF Gene Modified Autologous Tumor Cell (TAG) Vaccine

    Gene Therapy, 2013

  • Long Tem1 Follow Up: Phase I Trial of "bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell" Immunotherapy (FANG™) in Advanced Cancer

    Journal of Vaccines & Vaccination, 2013

  • Phase I Trial of "bi­ shRNA/urin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer

    Molecular Therapy, 2012

  • Phase I Trial of TGF-P2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

    Clinical Cancer Research, 2011

  • A Phase II, Single-arm Study of the Anti-a5p I Integrin Antibody Volociximab as Monotherapy in Patients with Platinum-resistant Advanced Epithelial Ovarian or Primary Peritoneal Cancer

    Gynecologic Oncology, 2011

  • Induction Oflmmune Responses and Clinical Efficacy in a Phase II Trial ofIDM- 2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic  Non-Small-Cell Lung Cancer

    Journal of Clinical Oncology, 2008

  • Hydatidiform Mole: 25 Years Experience at the Parkland Memorial hospital (PMH)

    International Journal of Gynecology and Obstetrics, 2003

Research Interest

Dr. Barve is the principal investigator for various studies through the Mary Crowley Medical Research Centers Network and has a special interest in vaccine-based and biologic therapies for cancer.

Other Information

Dr. Barve enjoys biking, traveling, hiking, music, healthy cooking, family time and her dogs.